Figure 1. Trends in Treatment with Erythropoiesis-Stimulating Agents Prior to End-Stage Renal Disease.
Panel A: Proportion of Patients Having Received Treatment with an Erythropoiesis-Stimulating Agent (any; epoetin alfa; darbepoetin alfa)
Panel B: Median Time from First Recorded Treatment with an Erythropoiesis-Stimulating Agent to End-Stage Renal Disease (in days)
Panel C: Adjusted Prevalence Rates of Erythropoesis-Stimulating Agent Use Prior to End-Stage Renal Disease (Referent: 1995)
Multivariable model adjusted for age, sex, race, Medicaid (“dual”) eligibility, comorbid diabetes, estimated glomerular filtration rate and body mass index at end-stage renal disease.